Meeting
2015 ASCO Annual Meeting
Smoking status to predict sensitivity to PARP inhibitor, veliparib, in patients with advanced NSCLC.
Authors
Suresh S. Ramalingam
Winship Cancer Institute of Emory University, Atlanta, GA
Suresh S. Ramalingam , Normand Blais , Julien Mazières , Martin Reck , C. Michael Jones , Erzsebet Juhasz , Laszlo Urban , Sergey Orlov , Fabrice Barlesi , Ebenezer A. Kio , Ulrich Keilholz , Jane Qian , Qin Qin , Martin Dunbar , Hao Xiong , Rajendar K. Mittapalli , Peter Ansell , Mark D. McKee , Vincent L. Giranda , Vera Gorbunova
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01560104
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8038)
DOI
10.1200/jco.2015.33.15_suppl.8038
Abstract #
8038
Poster Bd #
360
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.
First Author: Shannon L Puhalla
Poster
2018 ASCO Annual Meeting
A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101.
First Author: Michael J. Jelinek
Poster
2015 Breast Cancer Symposium
Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2- BRCA-associated locally advanced or metastatic breast cancer (BC).
First Author: Shannon Leigh Huggins-Puhalla
Poster
2015 ASCO Annual Meeting
Results of a randomized, global, multi-center study of whole-brain radiation therapy (WBRT) plus veliparib or placebo in patients (pts) with brain metastases (BM) from non-small cell lung cancer (NSCLC).
First Author: Pierre Chabot